Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.S. Equity News: ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting
Apr 23, 2007 (M2 PRESSWIRE via COMTEX) -- City of Industry, CA - Biotechnology
industry alert provided by U.S. Equity News. IgG1 monoclonal antibodies
developed by ImClone Systems Incorporated (NASDAQ: IMCL) were the focus of 44
total presentations at the recently concluded 98th Annual Meeting of the
American Association for Cancer Research (AACR), including seven oral
presentations and 37 posters. Important ERBITUX (cetuximab) clinical data were
the focus of two back-to-back oral presentations leading off the "Breakthroughs
in Clinical Research" Plenary Session on April 16, 2007, which highlights the
most important clinical studies presented at this prestigious meeting.
Wine vs. Water
It has been scientifically proven that if we drink 1 liter of water each day, at the end of the year we would have absorbed more than 1 kilo of Escherichia coli (E. coli) bacteria found in feces.
In other words, we are consuming 1 kilo of Poo. However, we do not run that risk when we are drinking wine or (whiskey, rum, beer or other liquor) because alcohol has to go through a purification process of boiling, filtering and/or fermenting.
WATER = Poo
WINE = HEALTH
Ergo: It is better to drink wine and talk stupid than to drink water and be full of crap.
There isn't need to thank me for this valuable information; I am doing it as a public service!
Are wet kisses kosher?????
Amen to that!!!
An 80-year old Italian man goes to the doctor for a check-up.
The doctor is amazed at what good shape the guy is in and asks, "How do
you stay in such great physical condition?"
I'm Italian and I am a golfer," says the old guy," and that's why I'm
in such good shape." I'm up well before daylight and out golfing up
and down the fairways. Have a glass of vino, and all is well."
"Well," says the doctor, "I'm sure that helps, but there's got to be
more to it. How old was your Dad when he died?"
"Who said my Dad's dead?"
The doctor is amazed "You mean you're 80 years old and your Dad's
still alive. How old is he?"
"He's 100 years old," says the old Italian golfer. "In fact he golfed
with me this morning, and then we went to the topless beach for a
walk, that's why he's still alive ... he's Italian and he's a golfer, too."
"Well," the doctor says, "that's great, but I'm sure there's more to
it than that. How about your Dad's Dad? How old was he when he died ?"
"Who said my grandpa's dead?"
Stunned, the doctor asks, "You mean you're 80 years old and your
grandfather's still living! Incredible, how old is he?"
"He's 118 years old," says the old Italian golfer. The doctor is
getting frustrated at this point, "So, I guess he went golfing with
you this morning too?"
"No. Grandpa couldn't go this morning because he's getting married today."
At this point the doctor is close to losing it. "Getting married!!
Why would a 118 year-old guy want to get married?"
"Who said he wanted to?"
Some more material for you to read and understand
http://www.faulkingtruth.com/Articles/LettersToEditor/1040.html
Wall Street vs. Main Street: Part 2-Oklahoma counts down the days
By Mark Faulk
April 20, 2007
Oklahoma SB 979, which addresses fails to deliver in the stock market, is scheduled to be voted on by the Oklahoma House of Representatives early next week, probably on Tuesday. The Oklahoma Securities Commission and Securities Administrator Irving Faught are opposing SB979. This legislation is important, not only to Oklahoma, but to other states that are working on similar laws.
I spoke with Faught earlier this week, and he told me that the NASAA was opposing Oklahoma’s SB979 because it was “unconstitutional, unenforceable, and poorly-written.” However, the NASAA has stated that they NOT opposing SB979, and that they are remaining neutral on state legislation. I am still awaiting a response to my emails and phone calls from NASAA General Council Rex Staples. The NASAA has been a strong supporter of stock market reform both at the federal and state level.
I believe that Mr. Faught truly wants reform in the stock market, but his comments to me that he’s “relying on the SEC to eliminate the grandfather clause in Reg SHO” suggest that he might not have a grasp as to how complicit the SEC is in this system-wide failure. The countdown to the vote in Oklahoma comes as Overstock.com CEO Patrick Byrne “celebrates” 500 days on the Reg SHO list, which lists companies that have significant amounts of stock that has been sold by brokers, but never delivered to customers.
To read the rest of this article, and for information on how you can help ensure the passage of Oklahoma SB979, go to:
http://www.faulkingtruth.com/Articles/LettersToEditor/1040.html
I.m sorry but your theory is about as atrocious a statement that I have ever read. Do you realize that Vergis at one point hired a German Security lawyerr in an attempt to force the German Bourse to delist NMKT which they placed in play without even the courtesy of talking to PHIL?? It turned out that even with help from our SEC the Germans were adamant in their refusal becaiuse naked shorting is legal in Germany. No company has ever naked shorted thier own shares. Fromw where did you ever get such an outlandish idea?
If naked shorting as you understand it could not happen why is NMKT on the SEC's SHO list which shoiws company's whose stock is naked shorted????Go look at it for yourself and get a bit of education on the subject.
Want to post youyr guess as to the market size VCST is addressing??
I agree-as for me I pose thew probability that NMKT is a prime target of naked shorters. But that is going to change shortly-
Score one for you!!
Diamond I Shareholder Update on First Year Revenue Forecast of $10 Million With Combined Wi-Fi Assets of Diamond and NewMarket
Spin-Off a Key Component of NewMarket Technology's Plan for Increasing Shareholder Value
LAS VEGAS, NV--(MARKET WIRE)--Apr 19, 2007 -- Diamond I, Inc. (OTC BB:DMOI), a developer of wireless gaming products, including the GS2(TM) wireless hand-held gaming unit and the WifiCasino(TM) wireless gaming system, today provided additional clarification of its previously announced spin-off of its gaming subsidiary, Diamond I Technologies.
As previously announced, NewMarket Technology (OTC BB:NMKT) will consolidate its own Wi-Fi assets into Diamond to build a comprehensive wireless broadband offering with applications in multiple market segments. Initially, the municipal government and casino/gaming sectors will be targeted. The 1st Year revenue forecast with the combined Wi-Fi assets of Diamond and NewMarket is approximately $10 million. The Diamond I name will be changed to NewMarket Broadband, Inc. and the ticker symbol will change by June 1.
Additionally, NewMarket Technology is in the process of acquiring a majority interest in Texas-based RedMoon Broadband to further strengthen the new NewMarket subsidiary, NewMarket Broadband. An announcement on the closing is pending. RedMoon Broadband is a leader in municipal Wi-Fi and has designed, engineered and deployed wireless mesh network solutions, providing high-speed Internet service, security surveillance, automatic meter reading and mobile broadband for municipalities.
To assist cities in rapidly launching their Wi-Fi networks, the RedMoon Broadband has created the RedMoon Starter Kit, conveniently bundling all that's required to build a secure 2.4 GHz Wi-Fi and 4.9 GHz Public Safety HotZone including SkyPilot mesh nodes, video surveillance cameras, and a complete Support System. Although managed by the state of Texas, other state agencies and local government entities are able to benefit from the Go DIRect Program based upon eligibility.
Diamond I shareholders of record on a date yet to be determined, but anticipated to be prior to June 1, 2007, will receive shares in he new gaming subsidiary. Diamond I Technologies is to receive $750,000 in funding under the agreement with NewMarket.
In addition to the $750,000 in funding to Diamond I's Gaming Subsidiary, under the agreement with NewMarket, NewMarket will purchase two million shares of a new series of preferred stock of Diamond I, in exchange for (1) a $2,000,000 promissory note, (2) a $250,000 credit line, $25,000 of which is available immediately, and (3) a commitment for an additional $1,000,000 in funding (terms to be negotiated) for Diamond I's revived WIFI division. Diamond I shareholders of record on the closing date of the agreement with NewMarket will be entitled to their pro rata share of the $2,000,000 received under the promissory note and will be entitled to their pro rata share of the stock of Diamond I's gaming subsidiary. The new series of preferred stock to be issued to NewMarket will possess voting rights that give NewMarket voting control of Diamond I.
All interested investors and shareholders interested in being added to the DMOI corporate e-mail list should send an e-mail to ir@newmarkettechnology.com.
About Diamond I, Inc. (www.wificasino.net)
"Voice-Print" and "Finger-Print" Technologies. Diamond I owns the rights to patent-pending voice-recognition and fingerprint biometric security technologies. These security technologies will be incorporated into Diamond I's WifiCasino GS wireless, hand-held gaming system, as well as the hand-held gaming unit to be employed by the Global Gaming Platform venture.
Diamond I, Inc. is a development-stage company that develops wireless gaming products, including a hand-held Wi-Fi-based gaming system for on-premises use by casinos/resorts, known as "WifiCasino"(TM), which includes the GS2(TM), the user-friendly wireless hand-held unit. The term "Wi-Fi" (wireless fidelity) refers to an industry standard for wireless equipment that meets published 802.11(x) standards. Wi-Fi equipment operates in unlicensed spectra, such as 2.4 and 5.8 Ghz.
With the passage of Nevada Law AB471, which authorizes the use of mobile communication devices for gaming in public areas in Nevada casinos, Diamond I seeks to secure a Las Vegas hotel/casino to serve as the demonstration site for its WifiCasino, in conjunction with its application for a gaming license in Nevada. To that end, in a letter of intent, The Palms Resort and Casino has agreed to continue to develop a working relationship relating to Diamond I's WifiCasino and, assuming Diamond I continues to meet certain standards, The Palms stated that it intends to pursue an opportunity with Diamond I. Diamond I continues to seek venues in which to establish its WifiCasino system, including other U.S. casinos and horse and dog racing facilities. Diamond I has had preliminary discussions with certain owners of cruise ships, certain owners of horse racing facilities in the United States and dog and horse racing facilities outside the United States.
I'm with you BooBoo!
Not a problem. One more quater's results matching the one we just ended should really drive us out of the doldrums/ Increased public awarness of the company due to every increasing publicity will shake the naked shorters.
Not Weird nor funny-Just Sad
EVERYBODY OUGHTTA KNOW
Do you know?
I didn't know!
How could we?
Did you know that 47 countries' have reestablished their embassies in Iraq?
Did you know that the Iraqi government currently employs 1.2 million Iraqi people?
Did you know that
3100 schools have been renovated,
364 schools are under rehabilitation,
263 new schools are now under construction and
38 new schools have been completed in Iraq?
Did you know that Iraq's higher educational structure consists of
20 Universities, 46 Institutes or colleges and
4 research centers, all currently operating?
Did you know that
25 Iraq students departed for the United States in January 2005 for the re-established Fulbright program?
Did you know that the Iraqi Navy is operational?
They have 5 - 100-foot patrol craft,
34 smaller vessels and a naval infantry regiment.
Did you know that Iraq's Air Force consists of three operational squadrons, which includes 9 reconnaissance and 3 US C-130 transport aircraft
(under Iraqi operational control) which operate day and night and will soon add 16 UH-1 helicopters and 4 Bell Jet Rangers?
Did you know that Iraq has a counter-terrorist unit and a Commando Battalion?
Did you know that the Iraqi Police Service has over 55,000 fully trained and equipped police officers?
Did you know that there are
5 Police Academies in Iraq that produce over
3500 new officers each 8 weeks?
Did you know there are more than
1100 building projects going on in Iraq? They indicate:
364 schools,
67 public clinics,
15 hospitals,
83 railroad stations,
22 oil facilities,
93 water facilities and
69 electrical facilities.
Did you know that 96% of Iraqi children under the age of 5 have received the first 2 series of polio vaccinations?
Did you know that 4.3 million Iraqi children were enrolled in primary school by mid October?
Did you know that there are 1,192,000 cell phone subscribers in Iraq and phone use has gone up 158%?
Did you know that Iraq has an independent media that consists of
75 radio stations,
180 newspapers and
10 television stations?
Did you know that the Baghdad Stock Exchange opened in June of 2004?
Did you know that 2 candidates in the Iraqi presidential election had a
televised debate recently?
~OF COURSE WE DIDN'T KNOW~
WHY DIDN'T WE KNOW?
~OUR MEDIA WOULDN'T TELL US!~
Instead of reflecting our love for our country, we get photos of flag burning incidents at Abu Ghraib and people throwing snowballs at the presidential motorcades.
Tragically, the lack of accentuating the positive in Iraq serves two
purposes:
It is intended to undermine the world's perception of the United States thus minimizing consequent support,and it is intended to discourage American citizens.
---- Above facts are verifiable on the Department of Defense web site.
.......Pass it on! Give it a Wide Dissemination!
Red Hot Penny Stock: West Point grad leaves Wall Street dumbfounded after he makes dot-com-era business model work
A Taipan Financial News Research Alert
by Andrew Mickey, Editor, BreakAway Investor
March 2, 2007 -- UPDATED April 18, 2007
Sign up to receive DMA for FREE
"Early investors could reap 262% thanks to his staggering success"
The late 1990s were a great time to be an investor. We were all geniuses. After all, who wasn't making money? Every stock, no matter how ridiculous, did nothing but go up. One poster child for the dot-com bubble, both in its upward and downward trajectory, was CMGI (CMGI:NASDAQ). Over the years that followed, CMGI has grown into a mildly successful supply chain management firm. But it was its venture capital business that sent its stock soaring seven years ago.
CMGI was just ahead of its time. As a venture capitalist, it was charged with uncovering, investing in and developing new technologies. And when it brought those technologies to market, that's when the big payoff would come. CMGI was supposed to act as an incubator for new technologies and provide them with the financing and marketing expertise that would make them successful products. But the big payday never came. CMGI failed to take off -- and Wall Street made clear how it felt. CMGI shares plummeted from an all-time high of more than $160 down to less than $2 per share.
Red Hot Penny Stock: Wall Street's Completely Dumbfounded
That's why Texas-based Newmarket Technology (NMKT:OTC BB) is making waves in the business world. Many are left wondering how it was able to successfully use an incubator business model to create such tremendous growth in revenues.
Here's the deal. Newmarket isn't your average stock. In fact, it's a highly complicated business model. You see, Newmarket is a true incubator. It's growing a multitude of businesses and spinning them off. Newmarket shareholders receive additional shares of the new companies when they are spun off. Essentially, it's like receiving regular dividends. In this case, the dividends are in the form of shares of the newly created subsidiaries.
So far, Newmarket has successfully spun off Newmarket China (NMCH:OTC BB) and Diamond I (DMOI:OTC BB) into stand-alone companies. It has also spun off its Latin American operations by selling them to Paragon Financial (PGNF:Pink Sheets).
Just around the corner, Newmarket is going to spin off its VoIP subsidiary. And even though Newmarket has proven its growth potential in China and Latin America, the VoIP segment is probably the most exciting. The VoIP division is headed up by former Qwest Communications COO Peter Geddis. If you're a serious investor, Geddis' association with Qwest should be setting off alarm signals.
Qwest is a Baby Bell that has been through one of the greatest accounting scandals in history. At the time, the scandal rivaled those at Worldcom, Global Crossing and Enron. But it's nothing to worry about. Geddis left Qwest long before any of the fraud and abuse started. The incubator business model scares away many investors and allows Newmarket to quietly grow into a technology powerhouse. And granted, it is a bit complicated, but there are so many benefits to it that Newmarket has only begun to take advantage of.
Red Hot Penny Stock: But It Works, Plain and Simple
Newmarket has a long track record of meeting its goals. Since the company really got its growth rolling, it has successfully met every goal for increasing revenues each time. The systems integrator and incubator has a history of big promises, but always delivers. At the end of 2004, the company boasted it would generate $50 million in revenues in 2005. Wall Street laughed. But Newmarket delivered.
At the start of 2006, Newmarket claimed it was going to rake in more $70 million in 2006. Despite the lofty goal, Nemarket performed handily. In fact, the company announced it exceeded it by 10.8%. On top of that, this red hot penny stock is profitable. That's rare indeed for a company that is growing this fast.
And, on January 18, Newmarket made its boldest claim yet. It called for a rebound of growth in 2007 with revenues of $120 million and it expects to reach $500 million in revenues by 2010. I realize these are some pretty big goals, but Newmarket has an excellent track record.
Right now, the company's stock price doesn't reflect the potential of this achievement. If the company is able to reach its $500 million goal, you're going to be holding an $8 stock. As discriminating investors, we need to look at the worst-case scenario. After all, what if Newmarket completely stumbles and only books $250 million in revenues in 2010? Well, we're looking at a stock in the $2 to $3 range.
So even when looking at the worst-case scenario, the stock still has the realistic potential to generate 52% annualized returns. And there's no way the S&P 500 is going to keep up with that.
Dynamic Market Alert
Your Premier Investment Insight
"For more than a year I've followed your results and comments... the only word I can use to describe my experience is 'fantastic'." -- John, member
Written by J. Christoph Amberger, Dynamic Market Alert offers you the revolutionary investing insight of Dynamic Market Theory -- a system that moves with the ever-changing stock market, and helps you profit when it changes... before the rest of the investing herd can act. Cited as "far and away the premier free investment service...", Dynamic Market Alert gives you access to a global network of experts, profitable investment insight, urgent alerts -- all in a FREE daily e-mail.
Begin receiving the Dynamic Market Alert today. Enter your e-mail address below and click the Join Us button.
We value your privacy!
We value your privacy. We will not share your e-mail address with anyone else.
Jeanne Smith, Director, Dynamic Market Alert
Red Hot Penny Stock: Plan for Success
Newmarket Technology offers its shareholders many benefits besides just owning a rapidly growing company and undervalued stock. One of its most attractive features is that it will be cranking out stock dividends over the next year and a half.
Officially, Newmarket plans to issue three stock dividends over the upcoming 18 months. Keep in mind that means you?ll be getting shares in Newmarket?s subsidiaries in addition to what you already own. It?s the stock that keeps on giving.
And Newmarket has done a great job launching subsidiaries publicly so far. To date, ther are three:
Diamond I (DMOI:OTCBB)
Paragon Financial Corp (PGNF:OTCBB)
Newmarket China (NMCH:OTCBB)
Over the next 18 months the stock dividends will be coming in the form of shares of these companies.
Red Hot Penny Stock: Making the List
Newmarket has successfully joined a pretty exclusive club. Each year Big Four accounting firm Deloitte & Tousche publishes multiple lists of the fastest-growing companies in the world. The lists give a great picture of how Newmarket stacks up against other technology companies around the world.
And it does very well. Since 2001, Newmarket has grown its revenues from less than $1 million to more than $65 million in 2006. Between 2001 and 2005, Newmarket grew 31,633%.
It's growth like this that caught the attention of researchers at Deloitte. Newmarket has been so successful at developing and marketing systems integration technology that it reached No. 5 on the list of the 500 fastest-growing tech companies in North America. The company also ranked No. 1 among all businesses in Texas.
Clearly, Newmarket has been able to turn the much-maligned incubator business model into an astounding success. And now it's going to start spinning off many of its businesses that it has spent the last few years getting off the ground.
Red Hot Penny Stock: Not One to Bet Against
Newmarket's CEO, Philip Verges, is not one to bet against. Not only has he grown Newmarket into a multimillion-dollar enterprise in less than five years since completing his service requirement with the U.S. Army, but he's a firm believer in the future of his company. True belief from top management is not always there in the world of penny stocks. There are a lot of unscrupulous people trying to take advantage of unsuspecting investors. That's not the case with Newmarket.
Just look at the top Newmarket stockholders. Topping the list is Verges. In fact, he currently owns 63 million shares of Newmarket stock, or 38.3% of all outstanding stock -- by far and away the largest shareholder. With a massive holding like that, you can bet his interests are right in line with yours.
Red Hot Penny Stock: Action to take
Buy shares of Newmarket Technology (NMKT:OTC BB) under 45 cents per share. This small Texas company has been making a killing helping major businesses around the world function. It has become a key partner to customers throughout high-growth regions including Latin America and China. Shares won't be hanging around under a dollar for too much longer.
Keep in mind that this is a penny stock: As such it is likely to move dramatically on inorganic volume and demand spikes.
NewMarket Technology, Inc Reports 55% Revenue Increase to $77.6 Million in 2006 with 38% Net Income Growth to $4 Million in SEC Form 10K Annual Report
Fourth Quarter Revenue Hits $24.5 Million with Record Quarterly Net Income of $1.7 Million
DALLAS--(BUSINESS WIRE)--NewMarket Technology, Inc. (OTCBB:NMKT) today announced filing SEC Form 10K to report on the Company's 2006 business operations and financial performance. The Company reported $77.6 million in revenue exceeding a $70 million forecast by 11% and increasing revenue by 55% over 2005. Net income increased 38% from $2.9 million in 2005 to $4.0 million in 2006.
Philip Verges, CEO of NewMarket Technology, Inc., said, "All financial indicators in the 2006 Annual report demonstrate substantial growth over 2005 as well as the maturing of NewMarket's overall operation. Significantly, our Fourth Quarter for 2006 was $24.5 Million -- a 60% increase over Fourth Quarter 2005. We look forward to growing profitably to $120 million in 2007 revenue."
Financial Report Highlights
Balance Sheet:
Cash position up 25% over last quarter ($3.3m v. $2.6m)
Stockholder's equity up 32% from year-end 2005 ($43.2 v. $32.8m)
Statement of Operations:
Revenue for 2006 up 55% from 2005 ($77.6m v. $50.1m)
Revenue for 4th quarter 2006 up 60% over 4th quarter 2005 ($24.5m v. $15.3m)
Gross profit for 2006 up 18% from 2005 ($21.9m v. $18.6m)
Operating expense percentage down, 22% of sales in 2006 v. 31% of sales in 2005
Net income (before currency translation) for 2006 up 38% from 2005 ($4.0m v. $2.9m)
Net income for 4th quarter 2006 up 18% over 4th quarter 2005 ($1.7m v. $1.5m)
Cash Flow:
Cash flow from operations for 2006 was up 97% from 2005 ($2.9m v $1.5m)
Beacon Equity Research to Update NewMarket Report with Fair Market Value of $0.78
In conjunction with the Annual Report, Beacon Equity Research is updating its independent analyst report rating NewMarket as an "Outperform" with a fair market value of $0.78. The report was issued during the fourth quarter of 2006 and did not take into consideration the recent independent listing of consolidated subsidiaries and the just released record 2006 financials. NewMarket anticipates an updated research report to be released by Beacon Research this week.
The BreakAway Investor "Buy" Recommendation on NewMarket Updated
The BreakAway Investor of the Taipan Financial Network issued a "Buy" recommendation on NewMarket Technology. The BreakAway Investor investment report on NewMarket Technology is accessible at www.taipanfinancialnews.com/red-hot-penny-stock-update-0407.html.
Webcast Scheduled for Wed, April 25th at 4:30 pm EDT
NewMarket Technology management will conduct a webcast on April 25 at 4:30 pm EDT. Further details on the call are available at http://www.vcall.com/IC/CEPage.asp?ID=116193.
To be added to NewMarket's corporate e-mail list for shareholders and interested investors, please send an e-mail to ir@newmarkettechnology.com.
About NewMarket Technology, Inc. (www.newmarkettechnology.com)
NewMarket helps clients maintain the delicate balance between maintaining legacy systems and gaining a competitive edge from the latest technology innovations. NewMarket provides certified integration and maintenance services to support the prevailing industry standard solutions to include Microsoft (Nasdaq:MSFT), Cisco Systems (Nasdaq:CSCO), SAP (NYSE:SAP), Siebel (Nasdaq:ORCL) and Sun Microsystems (Nasdaq:SUNW). Concurrently, NewMarket continuously seeks to acquire undiscovered emerging technology assets to incorporate into an overall product portfolio carefully packaged to complement the prevailing industry standard solutions. NewMarket delivers its portfolio of products and services through its global network of Solution Integration subsidiaries in North America, Latin America, China and Singapore. NewMarket maximizes shareholder return on investment by independent listing of consolidated regional and emerging technology subsidiaries in order to issue subsidiary stock in shareholder dividends. NewMarket ranked Number Five on Deloitte's 2006 Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications and life sciences companies in North America. Rankings are based on percentage revenue growth over five years, from 2001-2005. The Company grew from less than $1 million in revenue in 2001 to over $50 million in profitable revenue in 2005.
Good news. Buyt remember that the proceeds to CLN wil;l be reduced by repayment of the $15M loan plus accrued interest. Even with this the news is very good.
Now that the reverse split is on the books what's next. Delisting is now not an immediate threat. Company needs cash to cointinue operating. In the very poor reimbursement arena which scanning plays a role sales will become harder to finalize-even with the new advertising campaign. Damadian can go for another private placement and failing the success of this he gould resort to death spiral financing. Either route will be another disaster for shareholders since their equity positions will again pay the bill.
Was hoping for different answer. Thanks.
What streaming equipment does YouTube use?
Clemson Study
A 2007 study by Clemson University found that the average American walks
about 900 miles per year.
Another study by the American Beer Institute found that Americans drink an
average of 22 gallons of beer a year.
That means, on average, Americans get approximately 41 miles per gallon -
not bad!
book report
Students were assigned to read 2 books, "Titanic" and "My Life" by Bill Clinton and turn in book reports on each of them. One sharp witted student
turned in the following book report, with the proposition that they were nearly identical stories and hence only one book report was required! His cool professor gave him an A+ for this report:
Titanic: $29.99 Clinton: $29.99 Titanic: Over 3 hours to read Clinton: Over 3 hours to read Titanic: The story of Jack and Rose, their forbidden love, and subsequent catastrophe. Clinton: The story of Bill and Monica, their forbidden love and subsequent
catastrophe. Titanic: Jack is a starving artist. Clinton: Bill is a bullshit artist. Titanic: In one scene, Jack enjoys a good cigar. Clinton: Ditto for Bill. Titanic: During ordeal, Rose's dress gets ruined. Clinton: Ditto for Monica. Titanic: Jack teaches Rose to spit. Clinton: Let's not go there. Titanic: Rose gets to keep her jewelry. Clinton: Monica's forced to return her gifts. Titanic: Rose remembers Jack for the rest of her life. Clinton: Clinton doesn't remember Jack. Titanic: Rose goes down on a vessel full of seamen. Clinton: Monica...ooh, let's not go there, either.
Titanic: Jack surrenders to an icy death. Clinton: Bill goes home to Hillary... basically, the same thing.
________________________________________________________________________
,
After all the years of continuing turmoil and losses -its about time.
CHINESE PROVERBS
"Virginity like bubble, one prick, all gone."
"Man who run in front of car get tiredMan who run behind car get
exhausted."
"Man with hand in pocket feel cocky all day."
"Foolish man give wife grand piano, wise man give wife upright organ."
"Man who walk through airport turnstile sideways going to Bangkok. "
"Man with one chopstick go hungry."
"Man who scratch ass should not bite fingernails."
"Man who eat many prunes get good run for money."
"Baseball is wrong: man with four balls cannot walk."
"Panties not best thing on earth! But next to best thing on earth."
"War does not determine who is right, war determine who is left."
*Wife who put husband in doghouse soon find him in cat house."
*Man who fight with wife all day get no piece at night.*
"It take many nails to build crib, but one screw to fill it."
"Man who drive like hell, bound to get there."
*Man who stand on toilet is high on pot."
"Man who live in glass house should change clothes in basement."
"Man who fish in other man's well often catch crabs."
"Man who fart in church sit in own pew.*
"Crowded elevator smell different to midget.*
New stock symbol FONRD Reverse stock split of 1/25. What next???
Definition of Marketing
The buzz word in today's business world is MARKETING. However, people
often ask for a simple explanation of "Marketing."
Well, here it is:
1. You're a woman and you see a handsome guy at a party. You go up to
him and say, "I'm fantastic in bed."
That's Direct Marketing
2. You're at a party with a bunch of friends and see a handsome guy.
One of your friends goes up to him and, pointing at you, says, "She's
fantastic in bed."
That's Advertising.
3. You see a handsome guy at a party. You go up to him and get his
telephone number. The next day you call and say, "Hi, I'm fantastic in
bed."
That's Telemarketing.
4. You see a guy at a party; you straighten your dress. You walk up to
him and pour him a drink. You say, "May I?" and reach up to straighten
his tie, brushing your breast lightly against his arm,and then say, "By
the way, I'm fantastic in bed."
That's Public Relations.
5. You're at a party and see a handsome guy. He walks up to you and
says, I hear you're fantastic in bed."
That's Brand Recognition.
6. You're at a party and see a handsome guy. He fancies you, but you
talk him into going home with your friend.
That's a Sales Rep.
7. Your friend can't satisfy him so he calls you.
That's Tech Support.
8. You're on your way to a party when you realize that there could be
handsome men in all these houses you're passing, so you climb onto the
roof of one situated towards the center and shout at the top of your
lungs,
"I'm fantastic in bed!"
That's Junk Mail.
9. You are at a party; this tall man walks up to you and grabs your ass.
That's Former President Clinton.
10. You like it, but twenty years later your
attorney decides you were offended.
That's America .
ViewCast Releases New Osprey-700 HD Audio/Video Capture Card
High-Definition Video Capture and Streaming Solution Offers HD-SDI and PCI Express Compatibility for Broadcasters and Content Owners
PLANO, Texas — April 16, 2007 — ViewCast Corporation (OTCBB: VCST - News), a leading global provider of high-quality audio and video communication products, today announced the release of its new high-definition (HD) video capture card, the Osprey-700 HD. The new Osprey-700 HD is an HD-SDI and SD-SDI A/V input card designed for broadcasters and content owners needing to repurpose HD and standard-definition (SD) content for IP video distribution and video-on-demand applications.
With the ability to meet all video resolution needs, from 1080i and 720p to SD, the Osprey-700 HD provides raw HD capture and HD input scaled to SD and lower resolutions appropriate for streaming. The Osprey-700 HD is an excellent choice for ingesting HD/SD video for archiving and/or transcoding.
The Osprey-700 HD card includes the new Osprey Aviator™ encoder management software, which features advanced audio and video pre-processing tools such as an audio dynamic-range compressor and graphic equalizer, advanced video de-interlacing, and a vector scope and waveform monitor. The Osprey-700 HD is compatible with Osprey Digital SimulStream® to allow the output of multiple streams from a single media source to multiple applications.
By utilizing the high-speed PCI Express bus, the Osprey-700 HD provides the bandwidth required for high-resolution video capture in applications for a wide range of HD resolutions including 1080i (60/59.94/50 Hz) and 720p (60/50 Hz).
The Osprey-700 HD offers HD-SDI/SD-SDI video input with embedded SDI audio. It also supports extraction of vertical blanking interval (VBI) data for closed-captioning and Teletext applications.
"The Osprey-700 HD is a high-end capture solution for content owners and content aggregators using SDI video capture sources — both HD and SD," said David Stoner, president of ViewCast. "It is the first HD-compatible product from ViewCast and part of the new PCIe family of ViewCast Osprey capture cards developed for next-generation, high-performance systems."
More information about the Osprey-700 HD and other ViewCast products is available online at www.viewcast.com.
How much do you know?
A stranger was seated next to a little girl on an airplane when the
stranger turned to her and said, "Let's talk. I've heard that flights go
quicker if you strike up a conversation with your fellow passenger."
The little girl, who had just opened her book, closed it slowly and said to
the stranger, "What would you like to talk about?"
"Oh, I don't know", said the stranger. "How about nuclear power?"
"OK", she said. "That could be an interesting topic. But let me ask you a
question first. A horse, a cow, and a deer all eat grass, the same stuff.
Yet a deer excretes little pellets, while a cow turns out a flat patty,
and a horse produces clumps of dried grass. Why do you suppose that is?"
The stranger thinks about it and says, "Hmmm, I have no idea."
So, she said, "Do you feel qualified to discuss nuclear power
when you don't know shit?"
How much do you know?
A stranger was seated next to a little girl on an airplane when the
stranger turned to her and said, "Let's talk. I've heard that flights go
quicker if you strike up a conversation with your fellow passenger."
The little girl, who had just opened her book, closed it slowly and said to
the stranger, "What would you like to talk about?"
"Oh, I don't know", said the stranger. "How about nuclear power?"
"OK", she said. "That could be an interesting topic. But let me ask you a
question first. A horse, a cow, and a deer all eat grass, the same stuff.
Yet a deer excretes little pellets, while a cow turns out a flat patty,
and a horse produces clumps of dried grass. Why do you suppose that is?"
The stranger thinks about it and says, "Hmmm, I have no idea."
So, she said, "Do you feel qualified to discuss nuclear power
when you don't know shit?"
Many will recall that on July 8, 1947 witnesses claim an “unidentified flying object” with five aliens aboard—sex unknown—crashed on a sheep and cattle ranch just outside Roswell, New Mexico.
This is a well known incident that many say has long been covered up by the US Air Force and Federal Government.
However, you may well not know that in the month of March 1948, exactly nine months after that historic day, Albert Gore, Jr.; Hillary Rodham; John F. Kerry; William Jefferson Clinton; Howard Dean; Harry Reid; Nancy Pelosi; Dianne Feinstein; Charles E. Schumer; and Barbara Boxer were born.
That piece of little known information has now cleared up a lot of things.
Many will recall that on July 8, 1947 witnesses claim an “unidentified flying object” with five aliens aboard—sex unknown—crashed on a sheep and cattle ranch just outside Roswell, New Mexico.
This is a well known incident that many say has long been covered up by the US Air Force and Federal Government.
However, you may well not know that in the month of March 1948, exactly nine months after that historic day, Albert Gore, Jr.; Hillary Rodham; John F. Kerry; William Jefferson Clinton; Howard Dean; Harry Reid; Nancy Pelosi; Dianne Feinstein; Charles E. Schumer; and Barbara Boxer were born.
That piece of little known information has now cleared up a lot of things.
Super new news
http://biz.yahoo.com/bw/070323/20070323005636.html?.v=1
Thanks. At least one state understands and is will to do something about it. What we really need is for New York State to follow this lead. The SEC will never act because to do so will slam the revolving door with Wall Street in their faces. What a monstrous conflict of interest.
YAWN YAWN YAWN.
I agree with you except that I know it is good for shareholders.
Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
NEW YORK, April 10, 2007 /PRNewswire-FirstCall via COMTEX/ -- ImClone Systems Incorporated (Nasdaq: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that a Phase III study of ERBITUX(R) (Cetuximab) plus gemcitabine (a chemotherapy) in patients with locally advanced unresectable or metastatic pancreatic cancer did not meet its primary endpoint of improving overall survival.
Conducted by the Southwest Oncology Group (SWOG), a cancer center network sponsored by the National Cancer Institute, the open-label, randomized study compared ERBITUX plus gemcitabine to gemcitabine alone in more than 700 patients with pancreatic cancer in the first-line treatment setting. The study was conducted in centers throughout the United States and Canada. It was completed in a significantly shorter time than projected, providing a timely answer to an important research question. SWOG has informed ImClone and Bristol-Myers Squibb that the primary study endpoint of statistically improving overall survival was not met. The three parties -- SWOG, ImClone, and Bristol-Myers Squibb -- will engage in joint efforts to fully interpret these results.
"This study was designed to examine the Phase II results we previously observed for ERBITUX in patients with pancreatic cancer," stated Eric K. Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems. "We still consider pancreatic cancer to be of the utmost priority and we intend to pursue additional evaluations with ERBITUX including a pilot study of ERBITUX and bevacizumab with or without gemcitabine, as well as our pipeline agents, to improve the outcome for patients with pancreatic cancer."
"Pancreatic cancer is a devastating disease with few effective treatment options, and it is unfortunate that the use of ERBITUX in this trial has not demonstrated the benefit it has shown in other tumors," said Martin Birkhofer, M.D., Vice President, Oncology Global Medical Affairs, Bristol-Myers Squibb. "We are anxious to understand these data in greater detail and are committed to exploring the potential benefits that ERBITUX may provide to cancer patients."
This year in the U.S., approximately 33,700 people will be diagnosed with cancer of the pancreas. Pancreatic cancer accounts for about six percent (6%) of all cancer deaths, or about 32,000 deaths per year. The current 5-year survival rate is about five percent (5%). The number of deaths from this disease highlights the importance of seeking better therapies for pancreatic cancer through clinical trials testing novel drugs. During the past 30 years, the numbers of new cases of pancreatic cancer (incidence) and deaths (mortality) have changed little.
ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assays and in vivo animal studies have shown that binding of ERBITUX to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production. In vitro, ERBITUX can mediate antibody-dependent cellular cytotoxicity (ADCC) against certain human tumor types. While the mechanism of ERBITUX' anti-tumor effect(s) in vivo is unknown, all of these processes may contribute to the overall therapeutic effect of ERBITUX. EGFR is part of a signaling pathway that is linked to the growth and development of many human cancers, including those of the head and neck, colon and rectum.
ERBITUX (Cetuximab), in combination with radiation therapy, is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck. ERBITUX as a single agent is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed.
ERBITUX is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma (mCRC) in combination with irinotecan for patients who are refractory to irinotecan-based chemotherapy, and as a single agent for patients who are intolerant to irinotecan-based therapy. The effectiveness of ERBITUX for the treatment of EGFR-expressing mCRC cancer is based on objective response rates. Currently, no data are available that demonstrate an improvement in disease-related symptoms or increased survival with ERBITUX for the treatment of EGFR-expressing mCRC.
For full prescribing information, including boxed WARNINGS regarding infusion reactions and cardiopulmonary arrest, visit http://www.ERBITUX.com.
Grade 3/4 infusion reactions, rarely with fatal outcome (<1 in 1000), occurred in approximately 3% (46/1485) of patients receiving ERBITUX (Cetuximab) therapy. These reactions are characterized by rapid onset of airway obstruction (bronchospasm, stridor, hoarseness), urticaria, hypotension, and/or cardiac arrest. Severe infusion reactions require immediate and permanent discontinuation of ERBITUX therapy.
Most reactions (90%) were associated with the first infusion of ERBITUX despite the use of prophylactic antihistamines. Caution must be exercised with every ERBITUX infusion as there were patients who experienced their first severe infusion reaction during later infusions. A 1-hour observation period is recommended following the ERBITUX infusion. Longer observation periods may be required in patients who experience infusion reactions.
Cardiopulmonary arrest and/or sudden death occurred in 2% (4/208) of patients with squamous cell carcinoma of the head and neck treated with radiation therapy and ERBITUX as compared to none of 212 patients treated with radiation therapy alone. Fatal events occurred within 1 to 43 days after the last ERBITUX treatment. ERBITUX in combination with radiation therapy should be used with caution in patients with known coronary artery disease, congestive heart failure and arrhythmias. Close monitoring of serum electrolytes, including serum magnesium, potassium, and calcium during and after ERBITUX therapy is recommended.
Severe cases of interstitial lung disease (ILD), which was fatal in one case, occurred in less than 0.5% of 774 patients with advanced colorectal cancer (mCRC) receiving ERBITUX. There was one case of ILD reported in 796 patients with head and neck cancer receiving ERBITUX in clinical studies.
In clinical studies of ERBITUX, dermatologic toxicities, including acneform rash, skin drying and fissuring, and inflammatory and infectious sequelae (eg, blepharitis, cheilitis, cellulitis, cyst) were reported. In 208 patients receiving ERBITUX + RT, acneform rash was reported in 87% (17% severe) as compared to 10% in 212 patients treated with radiation therapy alone (1% severe). In patients receiving ERBITUX alone, 76% (N=103) experienced acneform rash (1% severe). In patients with mCRC, acneform rash was reported in 89% (686/774) of all treated patients, and was severe in 11% (84/774). Subsequent to the development of severe dermatologic toxicities, complications including S. aureus sepsis and abscesses requiring incision and drainage were reported. Sun exposure may exacerbate these effects. A related nail disorder, occurring in 12% (0.4% Grade 3) of patients, was characterized as a paronychial inflammation.
The safety of ERBITUX in combination with radiation therapy and cisplatin has not been established. Death and serious cardiotoxicity were observed in a single-am trial with ERBITUX, delayed, accelerated (concomitant boost) fractionation radiation therapy, and cisplatin (100 mg/m2) conducted in patients with locally advanced squamous cell carcinoma of the head and neck. Two of 21 patients died, one as a result of pneumonia and one of an unknown cause. Four patients discontinued treatment due to adverse events. Two of these discontinuations were due to cardiac events (myocardial infarction in one patient and arrhythmia, diminished cardiac output, and hypotension in the other patient).
The incidence of hypomagnesemia (both overall and severe [NCI CTC Grades 3 & 4]) was increased in patients receiving ERBITUX alone or in combination with chemotherapy as compared to those receiving best supportive care or chemotherapy alone based on ongoing, controlled clinical trials in 244 patients. Approximately one-half of these patients receiving ERBITUX experienced hypomagnesemia and 10-15% experienced severe hypomagnesemia. Electrolyte repletion was necessary in some patients and in severe cases, intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy.
The most serious adverse reactions associated with ERBITUX in combination with radiation therapy in 208 patients with head and neck cancer were infusion reaction (3%), cardiopulmonary arrest (2%), dermatologic toxicity (2.5%), mucositis (6%), radiation dermatitis (3%), confusion (2%), and diarrhea (2%).
The most serious adverse reactions associated with ERBITUX in mCRC clinical trials (N=774) were infusion reaction (3%), dermatologic toxicity (1%), interstitial lung disease (0.4%), fever (5%), sepsis (3%), kidney failure (2%), pulmonary embolus (1%), dehydration (5% in patients receiving ERBITUX with irinotecan, 2% in patients receiving ERBITUX as a single agent) and diarrhea (6% in patients receiving ERBITUX with irinotecan, 0.2% in patients receiving ERBITUX as a single agent).
The overall incidence of late radiation toxicities (any grade) was higher with ERBITUX in combination with radiation therapy compared with radiation therapy alone. The following sites were affected: salivary glands (65%/56%), larynx (52%/36%), subcutaneous tissue (49%/45%), mucous membranes (48%/39%), esophagus (44%/35%), skin (42%/33%), brain (11%/9%), lung (11%/8%), spinal cord (4%/3%), and bone (4%/5%) in the ERBITUX and radiation versus radiation alone arms, respectively.
The incidence of Grade 3 or 4 late radiation toxicities were generally similar between the radiation therapy alone and the ERBITUX plus radiation therapy arms.
The most common adverse events seen in patients with carcinomas of the head and neck receiving ERBITUX in combination with radiation therapy (n=208) versus radiation alone (n=212) were mucositis-stomatitis (93%/94%), acneform rash (87%/10%), radiation dermatitis (86%/90%), weight loss (84%/72%), xerostomia (72%/71%), dysphagia (65%/63%), asthenia (56%/49%), nausea (49%/37%), constipation (35%/30%) and vomiting (29%/23%). The most common adverse events seen in patients with carcinomas of the head and neck receiving ERBITUX as a single agent (N=103) were acneform rash (76%), asthenia (45%), pain (28%), fever (27%) and weight loss (27%).
The most common adverse events seen in patients with mCRC receiving ERBITUX with irinotecan (n=354) or ERBITUX as a single agent (n=420) were acneform rash (88%/90%), asthenia/malaise (73%/48%), diarrhea (72%/25%), nausea (55%/29%), abdominal pain (45%/26%), vomiting (41%/25%), fever (34%/27%), constipation (30%/26%), and headache (14%/26%).
ImClone Systems Incorporated is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.
Certain matters discussed in this news release may constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the company's ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company's filings with the Securities and Exchange Commission, including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, Bristol-Myers Squibb built a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hundreds of scientists at Bristol- Myers Squibb's Pharmaceutical Research Institute are studying ways to improve current cancer treatments and identify better, more effective medicines for the future.
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the development and commercialization of an investigational compound. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2006, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
I'd also ask to borrow that spray but without hair what good would that do??
Erbitux fails end points in pancreatic cancer trial